Omecamtiv Mecarbil is a myosin activator that is now in phase 3 clinical trials as a treatment for heart failure and Mavacamten is a myosin inhibitor that has just started phase 2 trials as a treatment for HCM. Here, MYH14 is linked to heart failure.